Noguchi Memorial Institute for medical research, the nation's leading medical authority is calling for volunteers to participate in a study. The study is being organised by the Epidemiology Department of the Institute. The study is a clinical trial of Lassa fever vaccine.
Lassa fever is a viral disease caused by the Lassa virus. Rats and mice are the source of the disease to humans. The disease, endemic in West Africa, kills thousands when outbreaks ensue. The disease was first discovered in Nigeria in the 1960s when it killed a missionary nun.
The disease can be very deadly. It a haemorrhagic fever like Ebola but Ebola is generally more deadly.
Participants in the study will help contribute to scientific advancement by helping scientists at Noguchi understand the efficacy of the vaccine. Compensational packages are available for volunteers taking part in the study. This study is needed for the control of Lassa fever vaccine West Africa.
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform